Clichy

• Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal Failure Recruiting
  2024-515160-32-00 4 2022-02-02 Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)
• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli … Recruiting
  2024-512953-26-00 5 2021-07-06 intermediate-stage hepatocellular carcinoma
• Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cance … Recruiting
  2024-515344-23-00 4 2021-06-17 local advenced pancreatic adenocarcinoma
• Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for … Recruiting
  2024-511904-18-00 10 2020-07-08 Pancreatic adenocarcinoma (PAC)
• An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with … Recruiting
  2023-507256-76-00 6 2020-01-14 Ulcerative colitis
• Prospective multicenter randomized double-blind study comparing caspofungin to placebo for the treatment of ICU yeast intra-abdominal infect … Recruiting
  2024-516266-11-00 5 2020-01-06 yeast intra-abdominal infection, peritonitis
• A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatoce … Recruiting
  2023-507689-26-00 5 2019-10-07 Histologically or cytologically confirmed Locoregional Hepatocellular
• Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer Recruiting
  2024-510580-28-00 5 2019-06-05 Middle or low locally advanced resectable rectal carcinoma
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting
  2023-506027-29-00 5 2014-10-01 Children, adolescents and adults with newly diagnosed diffuse intrinsi
• Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota tran … Ended recruitment
  2024-517078-52-00 5 2026-01-19 Patients operated with an IPAA for ulcerative colitis woth active recu
• A trial to assess the long-term safety and effectiveness of glepaglutide in patients with short bowel syndrome who have been previously trea … Ended recruitment
  2025-520775-81-00 5 2025-12-23 Short Bowel Syndrome
• A Phase 3 Trial Comparing Whether BEM/RZR is Similar to SOF/VEL in Patients with Hepatitis C Virus Infection Ended recruitment
  2025-521096-31-00 5 2025-10-02 Chronic Hepatitis C Virus (HCV) Infection
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Ended recruitment
  2024-515919-22-00 5 2025-06-02 Chronic Hepatitis D Virus (HDV) Infection
• REBALANCE UC : impact of Fecal Microbiota Transplantation in ulcerative colitis:a randomized, sham controlled trial Ended recruitment
  2024-511863-27-01 10 2024-12-06 Adult patients with ulcerative colitis diagnosed for at least 3 months
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• JAK1 inhibitor treatment of inflammatory liver adenomas Ended recruitment
  2023-505278-13-00 4 2024-10-01 -women with an inflammatory HCA proven at histology and with at least
• A Phase 2a Study of Efinopegdutide in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis Ended recruitment
  2024-510923-20-00 4 2024-09-16 Metabolic Dysfunction-Associated Steatohepatitis
• An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended recruitment
  2023-508219-21-00 5 2024-09-12 BTC - Biliary Tract Cancer
• A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati … Ended recruitment
  2022-502043-35-01 5 2024-04-24 Advanced Biliary Tract Cancers
• A study of continued treatment with regorafenib in participants with solid tumors who have participated in other Bayer studies Ended recruitment
  2023-507084-19-00 4 2024-03-07 Solid malignant tumors
• Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co … Ended recruitment
  2022-502948-13-00 4 2024-03-01 Hepatocellular Carcinoma

Showing 97–120 of 177 trials